Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2025-12-25 @ 6:59 PM
NCT ID:
NCT04996004
Pre Assignment Details:
A total of 76 participants were enrolled and treated in the study (Phase I: 9 participants and Phase II: 67 participants).
Recruitment Details:
The study consisted of two phases: Phase I (dose escalation) and Phase II (dose expansion). Phase I enrolled participants with high-grade leiomyosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, dedifferentiated liposarcoma, angiosarcoma and epithelioid sarcoma. Phase II enrolled participants with high-grade leiomyosarcoma. Participants were treated with ontorpacept (TTI-621) in combination with doxorubicin for the first 6 cycles and ontorpacept alone thereafter.
Study:
NCT04996004
Study Brief:
Results Section:
NCT04996004